Dementia in Parkinsonism

Overview

Journal Ann Indian Acad Neurol

Specialty Neurology

Date 2011 Aug 18

PMID 21847324

Citations 2

Affiliations

Soon will be listed here.

Citing Articles

Insights from a 7-Year Dementia Cohort (VALCODIS): ApoE Genotype Evaluation.

Baquero M, Ferre-Gonzalez L, Alvarez-Sanchez L, Ferrer-Cairols I, Garcia-Valles L, Pereto M J Clin Med. 2024; 13(16).

PMID: 39200877 PMC: 11355866. DOI: 10.3390/jcm13164735.

Characteristics and outcomes of elderly patients with Parkinson's disease hospitalized due to COVID‑19‑associated pneumonia.

Georgakopoulou V, Gkoufa A, Bougea A, Basoulis D, Tsakanikas A, Makrodimitri S Med Int (Lond). 2023; 3(4):34.

PMID: 37448768 PMC: 10336924. DOI: 10.3892/mi.2023.94.

References

Calderon J, Perry R, Erzinclioglu S, Berrios G, Dening T, Hodges J . Perception, attention, and working memory are disproportionately impaired in dementia with Lewy bodies compared with Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2001; 70(2):157-64. PMC: 1737215. DOI: 10.1136/jnnp.70.2.157. View

Gomez-Esteban J, Zarranz J, Velasco F, Lezcano E, Lachen M, Rouco I . Use of ziprasidone in parkinsonian patients with psychosis. Clin Neuropharmacol. 2005; 28(3):111-4. DOI: 10.1097/01.wnf.0000164297.91643.ff. View

Ondo W, Tintner R, Voung K, Lai D, Ringholz G . Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord. 2005; 20(8):958-63. DOI: 10.1002/mds.20474. View

Hobson P, Meara J . Risk and incidence of dementia in a cohort of older subjects with Parkinson's disease in the United Kingdom. Mov Disord. 2004; 19(9):1043-9. DOI: 10.1002/mds.20216. View

. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med. 1999; 340(10):757-63. DOI: 10.1056/NEJM199903113401003. View

Girotti F, Marano R, Grazzi L, Scigliano G, Caraceni T . Cognitive impairment in Parkinson's disease. J Neural Transm Suppl. 1986; 22:163-70. View

Owen A, James M, Leigh P, Summers B, Marsden C, Quinn N . Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain. 1992; 115 ( Pt 6):1727-51. DOI: 10.1093/brain/115.6.1727. View

Jacobs D, Marder K, Cote L, Sano M, Stern Y, Mayeux R . Neuropsychological characteristics of preclinical dementia in Parkinson's disease. Neurology. 1995; 45(9):1691-6. DOI: 10.1212/wnl.45.9.1691. View

McKeith I, Galasko D, Kosaka K, Perry E, Dickson D, Hansen L . Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. 1996; 47(5):1113-24. DOI: 10.1212/wnl.47.5.1113. View

10.

Sabbagh M, Hake A, Ahmed S, Farlow M . The use of memantine in dementia with Lewy bodies. J Alzheimers Dis. 2005; 7(4):285-9. DOI: 10.3233/jad-2005-7403. View

11.

Friedman J, Berman R, Goetz C, Factor S, Ondo W, Wojcieszek J . Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord. 2006; 21(12):2078-81. DOI: 10.1002/mds.21091. View

12.

Sagar H, Cohen N, Sullivan E, Corkin S, Growdon J . Remote memory function in Alzheimer's disease and Parkinson's disease. Brain. 1988; 111 ( Pt 1):185-206. DOI: 10.1093/brain/111.1.185. View

13.

Litvan I, Mega M, Cummings J, Fairbanks L . Neuropsychiatric aspects of progressive supranuclear palsy. Neurology. 1996; 47(5):1184-9. DOI: 10.1212/wnl.47.5.1184. View

14.

Channon S, Jones M, Stephenson S . Cognitive strategies and hypothesis testing during discrimination learning in Parkinson's disease. Neuropsychologia. 1993; 31(1):75-82. DOI: 10.1016/0028-3932(93)90082-b. View

15.

Errea J, Ara J . [Cognition deterioration in Parkinson's disease: associated risk factors]. Rev Neurol. 1999; 28(5):439-43. View

16.

Growdon J, Corkin S . Cognitive impairments in Parkinson's disease. Adv Neurol. 1987; 45:383-92. View

17.

McKeith I, del Ser T, Spano P, Emre M, Wesnes K, Anand R . Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 2001; 356(9247):2031-6. DOI: 10.1016/S0140-6736(00)03399-7. View

18.

Emre M, Aarsland D, Albanese A, Byrne E, Deuschl G, De Deyn P . Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med. 2004; 351(24):2509-18. DOI: 10.1056/NEJMoa041470. View

19.

Matthews C, Haaland K . The effect of symptom duration on cognitive and motor performance in parkinsonism. Neurology. 1979; 29(7):951-6. DOI: 10.1212/wnl.29.7.951. View

20.

Marttila R, Rinne U . Dementia in Parkinson's disease. Acta Neurol Scand. 1976; 54(5):431-41. DOI: 10.1111/j.1600-0404.1976.tb04375.x. View